This article highlights the ongoing challenge in determining optimal treatment for serious Stenotrophomonas maltophilia infections. Despite evolving Infectious Diseases Society of America (IDSA) guidance, current evidence remains insufficient, emphasizing the need for robust clinical trials. The pathogen, a Gram-negative bacterium, is increasingly recognized for its resistance patterns and association with severe infections, particularly in immunocompromised patients. Effective management is complicated by its intrinsic resistance to many common antibiotics, making treatment selection difficult and often empirical. The lack of high-quality comparative studies means treatment decisions are frequently based on observational data or expert opinion, underscoring a significant gap in infectious disease research.
Key note: Randomized controlled trials are critically needed to establish evidence-based treatment guidelines for Stenotrophomonas maltophilia infections.